Ginkgo Bioworks Holdings, Inc.DNAEarnings & Financial Report
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...
DNA Q3 2025 Key Financial Metrics
Revenue
$38.8M
Gross Profit
N/A
Operating Profit
$-90.0M
Net Profit
$-80.8M
Gross Margin
N/A
Operating Margin
-231.8%
Net Margin
-207.9%
YoY Growth
-56.4%
EPS
$-1.45
Financial Flow
Ginkgo Bioworks Holdings, Inc. Q3 2025 Financial Summary
Ginkgo Bioworks Holdings, Inc. reported revenue of $38.8M for Q3 2025, with a net profit of $-80.8M (-207.9% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $38.8M |
|---|---|
| Net Profit | $-80.8M |
| Gross Margin | N/A |
| Operating Margin | -231.8% |
| Report Period | Q3 2025 |
Ginkgo Bioworks Holdings, Inc. Annual Revenue by Year
Ginkgo Bioworks Holdings, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $227.0M).
| Year | Annual Revenue |
|---|---|
| 2024 | $227.0M |
| 2023 | $251.5M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $34.8M | $37.9M | $56.2M | $89.0M | $43.8M | $48.3M | $49.6M | $38.8M |
| YoY Growth | N/A | -53.0% | -30.2% | 60.6% | 26.2% | 27.3% | -11.7% | -56.4% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.67B | $1.58B | $1.63B | $1.48B | $1.38B | $1.29B | $1.23B | $1.19B |
| Liabilities | $568.2M | $594.5M | $792.2M | $682.9M | $661.4M | $646.0M | $618.1M | $629.4M |
| Equity | $1.10B | $987.3M | $833.1M | $797.9M | $716.1M | $647.4M | $613.0M | $559.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-57.8M | $-89.3M | $-84.4M | $-103.5M | $-42.4M | $-51.5M | $-40.3M | $-31.6M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M